What Lanotan Treats: Main Uses and Benefits

Latanoprost is commonly used across conditions presenting with recurrent or episodic manifestations of high pressure, such as primary open-angle glaucoma and ocular hypertension. It is utilized for managing elevated pressure linked to these conditions. It is generally applied in settings marked by increased physiological stress on the optic nerve due to this pressure elevation, relevant in clinical settings that involve acute or unstable symptom patterns.

The medication is applied across domains where additional symptomatic support is needed to address the intraocular fluid pressure, which is considered a highly important factor for managing these conditions. Latanoprost supports patients during difficult episodes by slowing the disease progression and assisting with maintaining functional stability of the optic nerve. This helps patients cope more steadily with symptom fluctuations. It is generally considered relevant when supportive symptom management is appropriate, and may be part of symptomatic management in situations where combination assistance is required. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Intraocular Pressure The key benefit of Latanoprost is the sustained reduction of inner eye pressure that helps protect the optic nerve from damage, thereby supporting the preservation of sight.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Lanotan?

Lanotan (Latanoprost) is a prescription-only medication whose use is strictly defined by regulatory guidelines. Eligibility is primarily based on patient health status, age, and concurrent physiological conditions, as documented by authorities like the FDA and EMA.

Approved and Non-Eligible Populations

Population Group	Eligibility Status	Key Restriction Cited in Label
Adults (18+)	Approved	None (standard use)
Children/Adolescents	Not Recommended	Limited long-term safety data
Neonates	Contraindicated	Developmental stage; lack of safety data
Pregnant Women	Not Recommended	Safety not established in humans
Breastfeeding Women	Should Not Be Used	Risk of excretion into human milk

---

Absolute Contraindication and Cautions

Contraindication

Lanotan must not be used if a patient has a documented hypersensitivity or allergy to the active ingredient, Latanoprost, or any non-active ingredients (excipients) in the product.

Conditional Use (Caution)

Caution is required in patients with a history of intraocular inflammation (such as iritis or uveitis) or a history of herpetic keratitis. Conditional use is also specified for patients who are aphakic or pseudophakic with a torn posterior lens capsule, due to a heightened risk of cystoid macular oedema.

Interactions with other medicines and products

This section outlines the drug interaction information for Lanotan (Latanoprost) based strictly on official government-approved prescribing information, such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Interaction Domain	Practical Regulatory Constraint
Prostaglandin Analogues (e.g., Bimatoprost, Travoprost)	Not Recommended. The combined ophthalmic use of two or more prostaglandins or prostaglandin analogues is not advised, as regulatory reports indicate a risk of paradoxical elevation in intraocular pressure (IOP).
Other Topical Ophthalmic Drugs	Mandatory Timing Separation. If Lanotan is used with any other topical eye product, the drugs must be administered at least five (5) minutes apart to prevent dilution or washout.
Thimerosal-Containing Eye Drops	Mandatory Timing Separation. In vitro studies show precipitation occurs when Lanotan is mixed with eye drops containing thimerosal. These products must be administered at least five minutes apart.

Systemic Metabolic Interactions

Due to the minimal systemic absorption and rapid metabolism of Latanoprost after topical use, regulatory documents contain no definitive data regarding clinically significant systemic drug-drug interactions, including those mediated by metabolic enzymes (e.g., CYP pathways). No specific interactions with food, alcohol, or herbal products are officially documented.

How Lanotan Works: Molecular Mechanism

Lanotan (Latanoprost) operates by engaging specific molecular targets and pathways to facilitate the non-conventional drainage of fluid from the eye, resulting in the physiological consequence of reduced intraocular pressure.

---

Targeting the FP Receptor and Tissue Remodeling

The drug acts as a selective agonist for the Prostaglandin F receptor ( FP receptor), a protein found on the ocular ciliary muscle. Receptor activation initiates an enzymatic cascade that leads to the remodeling of the Extracellular Matrix ( ECM)—the tissue scaffolding—in the eye's drainage angle. This action functionally causes the ciliary muscle bundles to relax and physically loosens the surrounding tissues.

---

Enhancing Uveoscleral Outflow Dynamics

The structural remodeling and tissue loosening directly target and facilitate the Uveoscleral Outflow Pathway, the eye's non-conventional drainage route. This mechanism increases the tissue permeability and lowers outflow resistance within the tract, facilitating increased aqueous humor movement from the anterior chamber. This enhancement of fluid egress is the key mechanistic step that drives the physiological consequence of reduced Intraocular Pressure ( IOP).

---

Mechanism Limitations

The action relies on a complex, time-dependent structural change, resulting in a delayed peak effect (8–12 hours) compared to mechanisms that block immediate signaling. Furthermore, using the drug more frequently than once daily can lead to FP receptor subsensitivity or saturation, paradoxically causing a decrease in the magnitude of the resulting IOP reduction.

How to Use Lanotan: Official Administration Guidelines

Lanotan (Latanoprost) is prescribed as a Topical Ophthalmic Solution (usually 0.005% strength) intended for application directly to the eye. Adherence to the prescribed dosing regimen is crucial, as administering the medication more frequently than prescribed may diminish its intended pressure-lowering effect.

Standard Dosing and Schedule

Entity	Official Administration Protocol
Dosing Schedule	One drop in the affected eye(s); must not exceed once daily.
Timing	Administration should be performed in the evening for optimal therapeutic effect.
Missed Dose Rule	If a dose is missed, treatment should continue with the next dose as normal; do not double the dose.
Age-Group Rules	Adults and Older Adults follow the standard once-daily regimen. Posology is the same for pediatric patients from 4 years of age.

Procedural and Contextual Instructions

Proper use involves specific steps to ensure correct application and drug efficacy:

• Other Eye Drops: If using other topical ophthalmic medications, administer them at least five (5) minutes apart from Lanotan.
• Contact Lenses: Soft contact lenses must be removed prior to instillation and should not be reinserted until 15 minutes after the drops are administered.
• Administration Technique: To reduce potential systemic absorption, gently pressing the lachrymal sac at the medial canthus (punctal occlusion) for one minute following instillation is recommended.
• Dispensing Tip: The applicator tip must avoid contact with the eye or any surface to prevent contamination, which is essential for maintaining the sterility of the solution.

Use Protocol

This structured protocol defines the administration of the solution as a single drop applied once nightly, a regimen that is essential to maintain the product's function. The duration of the IOP-lowering effect supports this once-daily dosing requirement, beginning approximately 3 to 4 hours after administration and peaking at 8 to 12 hours.

Research Evidence / Overview of Studies for Lanotan

---

Evidence for Use in Open-Angle Glaucoma and Ocular Hypertension

The research base for Lanotan (Latanoprost) primarily consists of Randomized Controlled Trials (RCTs), which are a key study design for clinical evaluation. These studies were applied in research contexts involving high pressure, focusing on conditions characterized by functional limitations related to Intraocular Pressure (IOP). These studies evaluated adult patients diagnosed with either primary open-angle glaucoma or ocular hypertension.

Research examined the IOP measurement in millimeters of mercury (mmHg) from a starting baseline. Studies typically focused on short-term symptom changes observed over defined time intervals, usually up to a few months. Research highlights changes measured during the study period, with findings contributing to understanding the IOP patterns measured compared to the starting measurements. What remains uncertain is the full long-term impact on visual function, as follow-up durations for the pivotal efficacy trials were limited.

Research Evidence for Normal Tension Glaucoma

Lanotan was also evaluated in patients with Normal Tension Glaucoma (NTG), a condition marked by visual field loss despite normal-range IOP measurements. Research explored this group using a combination of smaller-scale RCTs and long-term observational research. In these populations, the key focus was on the rate of disease progression. Research describes patterns related to visual field deterioration, with some long-term observational findings describing patterns related to the rate of deterioration compared to historical rates.

Findings describe patterns related to measured IOP in these patients, even starting from a low baseline pressure. The volume of evidence for NTG is smaller compared to the research base for high-IOP indications. Evaluating the preservation of visual function requires very long follow-up periods; therefore, data are still emerging and long-term effects are not fully established.

Evidence Quality and Remaining Research Uncertainty

Key research limitation frames include that the primary efficacy results rely on studies where the follow-up durations were limited (e.g., typically three months), limiting the long-term data available. Data for certain groups, such as those with specific concurrent medical conditions, remain insufficient. While evidence suggests patterns related to IOP change, study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Common questions about Lanotan (FAQ)

Q: How soon after starting Lanotan can a person expect a change in eye pressure?

According to official product information, the reduction in eye pressure, known as Intraocular Pressure (IOP), generally begins approximately 3 to 4 hours after the drop is administered. The maximum or peak pressure-lowering effect is typically reached within 8 to 12 hours of application.

Q: How long is an opened bottle of Lanotan eye drops good for before it must be discarded?

Official instructions describe that once a multi-dose bottle of Lanotan is opened, it is recommended to be used or discarded within four weeks (28 days). This guideline helps maintain the sterility and stability of the solution. The specific product packaging contains the most precise expiration period for the formulation.

Q: Is having irritated or red eyes a normal side effect of using Lanotan?

Yes, regulatory documents classify both eye irritation (which includes stinging or burning sensations) and conjunctival hyperaemia (redness of the eye) as very common side effects. This means they are observed in a significant number of people who use the medication, as reported in clinical studies.

Q: Is it safe to use Lanotan if I am planning to become pregnant?

Official information states that Lanotan is not recommended for use by women who are pregnant or are attempting to become pregnant. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Information regarding the use of Lanotan during pre-conception planning is typically reviewed with a healthcare provider.

Q: Is Lanotan a steroid or an antibiotic eye drop?

Lanotan is not classified as a steroid or an antibiotic. According to official prescribing information, it belongs to a class of medicines known as a Prostaglandin F2alpha analog. This means it is a synthetic compound designed to mimic certain natural chemicals in the eye to help lower fluid pressure.

Q: Is it true that Lanotan can cause a headache or dizziness?

Headache and dizziness are documented in official safety information as uncommon or rare adverse reactions. This means they are observed infrequently in people taking the medication, based on clinical study findings.

Q: Does Lanotan cure glaucoma or only help manage the condition?

Lanotan is officially indicated for reducing elevated Intraocular Pressure (IOP). The labeling describes its function as a pressure-lowering agent intended for the long-term management of conditions. Official documentation describes the medicine's role in managing pressure, and it is not described as a cure for the underlying condition.

Q: Can non-prescription lubricating eye drops be used while using Lanotan?

Official instructions require that if any other topical eye medication is used, it must be administered at least five (5) minutes apart from Lanotan. This time separation is intended to help ensure the Lanotan solution is not diluted or washed out, which could impact its absorption.

Q: Does Lanotan contain a preservative, and is that preservative safe?

The standard multi-dose formulation of Lanotan typically contains the preservative benzalkonium chloride. This is a common ingredient in many ophthalmic solutions, and its inclusion and concentration are reviewed as part of the regulatory approval process by official agencies.

Q: Is blurred vision a side effect that may occur when starting Lanotan?

Official safety information includes blurred vision as a documented adverse reaction to Lanotan. This is classified as an uncommon side effect, meaning it is observed infrequently in people during clinical studies.

Q: Is using Lanotan once a day enough for a full 24 hours of eye pressure control?

The official and established regimen is one drop once daily in the evening. This precise dosing schedule is based on the drug's duration of effect described in clinical studies, supporting its designation by regulatory agencies for once-daily use.

Official Storage and Disposal Instructions

Storage requirements for latanoprost (Lanotan) differ based on the container status:

Storage Status	Temperature Requirement	Shelf-Life and Protection
Unopened Multi-Dose	Refrigerate (2 C to 8 C)	Store in the outer carton to protect from light. Do not freeze.
Opened Multi-Dose	Room temperature (up to 25 C)	Must be used or discarded within four to six weeks. Keep container tightly closed.
Single-Dose Units	Room temperature	Use immediately upon opening; discard container immediately after use.

All latanoprost must be kept out of the sight and reach of children. Unused or expired medication, including opened multi-dose bottles after their use period, must be disposed of according to local regulatory requirements and should not be discarded in household waste or wastewater.